International Journal of Drug Policy
Volume 21, Issue 1 , Pages 4-9 , January 2010

Social and structural determinants of HAART access and adherence among injection drug users

  • Andrea Krüsi

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    • ,
  • Evan Wood

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Julio Montaner

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Thomas Kerr

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada
    • Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    • Corresponding Author InformationCorresponding author at: BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, B.C. V6Z 1Y6, Canada. Tel.: +1 604 806 9116; fax: +1 604 806 9044.

Received 12 January 2009 ,Revised 22 May 2009 ,Accepted 7 August 2009.

References 

  1. Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE, Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the “treating 3 million by 2005. Making it happen. The who strategy” (“3 by 5”). Addiction. 2006;101(9):1246–1253
  2. Andersen MD, Smereck GA, Hockman EM, Ross DJ, Ground KJ. Nurses decrease barriers to health care by “hyperlinking” multiple-diagnosed women living with HIV/AIDS into care. Journal of the Association of Nurses in AIDS Care. 1999;10(2):55–65
  3. Arnsten JH, Li X, Mizuno Y, Knowlton AR, Gourevitch MN, Handley K, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. Journal of Acquired Immune Deficiency Syndromes. 2007;46(Suppl (2)):S64–S71
  4. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278(1):63–65
  5. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndromes. 1999;21(2):114–119
  6. Baumohl J, Speiglman R, Swartz J, Strahl R. Substance abuse and welfare policy at the new century. Contemporary Drug Problems. 2003;30:501–537
  7. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infectious Disease Clinics of North America. 2007;21(1):149–179ix
  8. Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine. 2003;10(1):1–14
  9. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–1715
  10. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544–546
  11. Clarke S, Delamere S, McCullough L, Hopkins S, Bergin C, Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Medicine. 2003;4(1):33–37
  12. Conanan B, London K, Martinez L, Modersbach D, O’Connell J, O'Sullivan M, et al. Adapting your practice: Treatment and recommendations for homeless patients with HIV/AIDS. Nashville: Health care for the homeless clinicians network, national health care for the homeless council, Inc.; 2003;
  13. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS consortium. HIV cost and services utilization. Journal of Acquired Immune Deficiency Syndromes. 2000;25(2):115–123
  14. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Archives of Internal Medicine. 2005;165(6):618–623
  15. Donoghoe MC, Lazarus JV, Matic S. HIV/AIDS in the transitional countries of eastern Europe and central Asia. Clinical Medicine. 2005;5(5):487–490
  16. Escaffre N, Morin M, Bouhnik AD, Fuzibet JG, Gastaut JA, Obadia Y, et al. Injecting drug users’ adherence to HIV antiretroviral treatments: Physicians’ beliefs. AIDS Care. 2000;12(6):723–730
  17. Evans L, Strathdee S. A roof is not enough: Unstable housing, vulnerability to HIV infection and the plight of the SRO. International Journal of Drug Policy. 2006;17:115–117
  18. Galea S, Vlahov D. Social determinants and the health of drug users: Socioeconomic status, homelessness and incarceration. Public Health Reports. 2002;117(Suppl. 1):S135–145
  19. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. Journal of Acquired Immune Deficiency Syndromes. 2005;38(1):96–103
  20. Gee GC, Delva J, Takeuchi DT. Relationships between self-reported unfair treatment and prescription medication use, illicit drug use, and alcohol dependence among Filipino Americans. American Journal of Public Health. 2007;97:933–940
  21. Giddens A. The constitution of society. Cambridge: Polity; 1984;
  22. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. Aids. 1999;13(13):1763–1769
  23. Green TC, Grau LE, Blinnikova KN, Torban M, Krupitsky E, Iiyuk R, et al. Social and structural aspects of the overdose risk environment in St. Petersburg. Russia. International Journal of Drug Policy. 2009;20:270–276
  24. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis c virus coinfection: The Swiss HIV cohort study. Lancet. 2000;356(9244):1800–1805
  25. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16(13):1835–1837
  26. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine. 1997;337(11):725–733
  27. Hoffman HL, Castro-Donlan CA, Johnson VM, Church DR. The Massachusetts HIV, hepatitis, addiction services integration (hhasi) experience: Responding to the comprehensive needs of individuals with co-occurring risks and conditions. Public Health Reports. 2004;119(1):25–31
  28. Hogg R, Yip B, Kully C, Craib K, O'Shaughnessy M, Schechter M, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal. 1999;160(5):659–665
  29. Human, Rights, & Watch . Rhetoric and risk: Human rights abuses impending Ukraines's fight against HIV/AIDS. New York: Human Rights Watch; 2006;
  30. Institute of Medicine. (2006). Preventing HIV infection among injecting drug users in high risk countries: An assessment of the evidence: The National Academic Press.
  31. Katz MH, Cunningham WE, Fleishman JA, Andersen RM, Kellogg T, Bozzette SA, et al. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Annals of Internal Medicine. 2001;135(8 Pt 1):557–565
  32. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of highly active antiretroviral therapy discontinuation among injection drug users. AIDS Care. 2005;17(5):539–549
  33. Kerr T, Montaner J, Wood E. Supervised injecting facilities: Time for scale-up?. Lancet. 2008;372(9636):354–355
  34. Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antiviral Therapy. 2004;9(3):407–414
  35. Knowlton A, Arnsten J, Eldred L, Wilkinson J, Gourevitch M, Shade S, et al. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users. Journal of Acquired Immune Deficiency Syndromes. 2006;41(4):486–492
  36. Krüsi A, Small W, Wood E, Kerr T. An integrated supervised injecting program within a care facility for HIV-positive individuals: A qualitative evaluation. AIDS Care. 2009;21:638–644
  37. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. Case management is associated with improved antiretroviral adherence and cd4+ cell counts in homeless and marginally housed individuals with HIV infection. Clinical Infectious Diseases. 2006;43(2):234–242
  38. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the who collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103(9):1484–1492
  39. Liu H, Longshore D, Williams JK, Rivkin I, Loeb T, Warda US, et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS and Behavior. 2006;10(3):279–286
  40. Maher L, Dixon D. Policing and public health: Law enforcement and harm minimization in a street-level drug market. The British Journal of Criminology. 1999;39(4):488–512
  41. Malins P, Fitzgerald J, Threadgold T. Spatial ‘Folds’: Then entwining of bodies, risks and city spaces for women injecting drug users in Mebourne's Central Business District. Gender, Place and Culture. 2006;13(5):509–527
  42. Malta M, Carneiro-da-Cunha C, Kerrigan D, Strathdee SA, Monteiro M, Bastos FI. Case management of human immunodeficiency virus-infected injection drug users: A case study in Rio de Janeiro, Brazil. Clinical Infectious Diseases. 2003;37(Suppl 5):S386–391
  43. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction. 2008;103(8):1242–1257
  44. Mazlan M, Schottenfeld RS, Chawarski MC. New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Review. 2006;25(5):473–478
  45. Miller C, Chan K, Palepu A, Tyndall MW, Hogg RS, O'Shaughnessy MV. Socio-demographic profile and HIV and hepatitis C prevalence among persons who died of a drug overdose. Addiction Research and Theory. 2001;9(5):459–470
  46. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to haart in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The MANIF 2000 study group. AIDS. 2000;14(2):151–155
  47. Molitor F, Walsh RM, Leigh JP. Determinants of longer time from HIV result to enrollment in publicly funded care and treatment in California by race/ethnicity and behavioral risk. AIDS Patient Care STDS. 2002;16(11):555–565
  48. Moore D. Governing street-based injecting drug users: A critique of heroin overdose prevention in Australia. Social Science and Medicine. 2004;59:1547–1557
  49. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22–29
  50. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Journal of Acquired Immune Deficiency Syndromes. 1999;22(4):369–378
  51. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–536
  52. NAOMI (2008). Reaching the hardest to reach - treating the hardest-to-treat. Summary of the primary outcomes of the North American Medication Initiative (NAOMI). Vancouver.
  53. Olsen JA, Richardson J, Dolan P, Menzel P. The moral relevance of personal characteristics in setting health care priorities. Social Science and Medicine. 2003;57(7):1163–1172
  54. Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: The impact of incarceration and prison release on adherence and HIV treatment outcomes. Antiviral Therapy. 2004;9(5):713–719
  55. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Dependence. 2006;84(2):188–194
  56. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362(9392):1267–1274
  57. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358(9291):1417–1423
  58. Reyes JC, Robles RR, Colon HM, Matos TD, Finlinson HA, Marrero CA, et al. Homelessness and HIV risk behaviors among drug injectors in Puerto Rico. Journal of Urban Health. 2005;82(3):446–455
  59. Rhodes T. The ‘risk’ environment: A framework for understanding and reducing drug related harm. International Journal of Drug Policy. 2002;13:85–94
  60. Rhodes T. Risk environments and drug harms: A social science for harm reduction approach. International Journal of Drug Policy. 2009;20(3):193–201
  61. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee S. The social structural production of HIV risk among injecting drug users. Social Science & Medicine. 2005;61:1026–1044
  62. Rhodes T, Platt L, Sarang A, Vlasov A, Mikhailova L, Monaghan G. Street policing, injecting drug use and harm reduction in a Russian city: A qualitative study of police perspectives. Journal of Urban Health. 2006;83(5):911–925
  63. Rhodes T, Mikhailova L, Sarang A, Lowndes C, Rylkov A, Khutorskoy M, et al. Situational factors associated with drug injecting, risk reduction and syringe exchange practices in Togliatti city, Russian Federation: A qualitative study of micro risk environment. Social Science and Medicine. 2003;57:39–54
  64. Rompalo AM, Shah N, Mayer K, Schuman P, Klein RS, Smith DK, et al. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV epidemiology research study: On-site versus referral care. Journal of Acquired Immune Deficiency Syndromes. 2001;28(1):28–34
  65. Room R. Stigma, social inequality and alcohol and drug use. Drug and Alcohol Review. 2005;24(2):143–155
  66. Sambamoorthi U, Warner LA, Crystal S, Walkup J. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug & Alcohol Dependence. 2000;60(1):77–89
  67. Shannon K, Bright V, Duddy J, Tyndall MW. Access and utilization of HIV treatment and services among women sex workers in Vancouver's downtown eastside. Journal of Urban Health. 2005;82(3):488–497
  68. Shannon K, Kerr T, Allinott S, Chettiar J, Shoveller J, Tyndall MW. Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Social science & medicine. 2008;66(4):911–921
  69. Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW. Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work. International Journal of Drug Policy. 2008;19:140–147
  70. Sherer R, Stieglitz K, Narra J, Jasek J, Green L, Moore B, et al. HIV multidisciplinary teams work: Support services improve access to and retention in HIV primary care. AIDS Care. 2002;14(1):S31–44
  71. Small W, Kerr T, Betteridge G, Wood E, Montaner J. Adherence to HIV Treatment among HIV-Positive injection drug users within correctional environments in British Columbia. AIDS Care. 2009;21(6):708–714
  72. Small W, Kerr T, Charette J, Schechter M, Spittal P. Impacts of intensified police activity on injection drug users: Evidence from an ethnographic investigation. International Journal of Drug Policy. 2006;17(2):85–95
  73. Small W, Wood E, Lloyd-Smith E, Tyndall M, Kerr T. Accessing care for injection-related infections through a medically supervised injecting facility: A qualitative study. Drug and Alcohol Dependence. 2008;98(1–2):159–162
  74. Song JY, Safaeian M, Strathdee SA, Vlahov D, Celentano DD. The prevalence of homelessness among injection drug users with and without HIV infection. Journal of Urban Health. 2000;77(4):678–687
  75. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care. 1998;10(3):297–312
  76. Springer SA, Pesanti E, Hodges J, Macura J, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases. 2004;38(15):1754–1760
  77. Stein MD, Rich JD, Maksad J, Chen MH, Hu P, Sobota M, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. American Journal of Drug & Alcohol Abuse. 2000;26(2):195–205
  78. UNAIDS . HIV/AIDS prevention, treatment and care among injecting drug users and in prisons. Moscow: UNAIDS; 2005;
  79. WHO . Ottawa charter for health promotion. In: First International Conference on Health Promotion. Ottawa. 1986;
  80. WHO . HIV/AIDS treatment and care for injecting drug users: Clinical protocol for the who European region. Copenhagen: WHO Regional Office for Europe; 2006;
  81. WHO . The methadone fix. Bulletin of the World Health Organization. 2008;86:161–240
  82. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: Access, adherence and structural barriers in Asia and the former Soviet Union. International Journal of Drug Policy. 2007;18(4):246–254
  83. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: A review for clinicians and patients. Lancet Infectious Diseases. 2005;5(7):407–414
  84. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS. 2005;19(8):837–839
  85. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. Jama. 2008;300(5):550–554
  86. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection among Persons Who Have Died in the Era of Modern Antiretroviral Therapy. The Journal of Infectious Diseases. 2003;188(8):1164–1170
  87. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy. 2004;9(2):229–235
  88. Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. Canadian Medical Association Journal. 2004;170(10):1551–1556
  89. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: Two potential futures. AIDS. 2000;14(9):1229–1235
  90. Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–919

PII: S0955-3959(09)00113-3

doi: 10.1016/j.drugpo.2009.08.003

International Journal of Drug Policy
Volume 21, Issue 1 , Pages 4-9 , January 2010

Article Tools